Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of giving bortezomib together with vorinostat
and to see how well it works in treating patients with multiple myeloma who have undergone
autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with
vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells
that remain after transplant.